GlassScriptPhysician profile
Gina Lesnik
NPI 1164418653
$10,557.11
in general payments reported to CMS, 2019-2025
36 companies · $807 in 2025
The $807 reported for 2025 was more than what 82% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,994 · 2020: $1,312 · 2021: $2,142 · 2022: $2,857 · 2023: $1,034 · 2024: $412 · 2025: $807.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,210 · Education: $42.25.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,210.40 |
| Education | $42.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $3,686.08 | 2019-2022 | |
| Abbvie INC. | $2,601.97 | 2021-2025 | |
| Amgen INC. | $499.84 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $439.48 | 2019-2022 | |
| Lilly USA, LLC | $392.64 | 2019-2022 | |
| Merz North America, INC. | $368.51 | 2019-2023 | Xeomin |
| Novo Nordisk INC | $366.24 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $364.76 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $299.28 | 2019-2022 | |
| Pfizer INC. | $244.56 | 2019-2022 | |
| Galderma Laboratories, L.P. | $195.50 | 2019-2025 | Dysport |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $160.33 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $125.59 | 2019-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $118.62 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $115.49 | 2019-2021 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $77.77 | 2021-2022 | |
| Glaxosmithkline, LLC. | $55.26 | 2020-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $50.18 | 2019-2021 | |
| Astellas Pharma US INC | $45.10 | 2020-2022 | |
| Ironshore Pharmaceuticals INC. | $39.86 | 2019 | |
| Shire North American Group INC | $39.12 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $29.61 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $27.93 | 2019-2020 | |
| Philips North America LLC | $23.53 | 2022 | |
| Novartis Pharmaceuticals Corporation | $22.19 | 2021 | |
| Dexcom, INC. | $19.82 | 2021 | |
| Genentech USA, INC. | $18.00 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $17.92 | 2021 | |
| Mylan Specialty L.P. | $17.48 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $16.54 | 2022 | |
| Cranial Technologies, INC | $14.86 | 2021 | |
| Eisai INC. | $14.54 | 2020 | |
| Impel Pharmaceuticals INC. | $13.63 | 2022 | |
| Romark Laboratories, Lc | $12.66 | 2019 | |
| Nalpropion Pharmaceuticals LLC | $11.14 | 2019 | |
| Arbor Pharmaceuticals, INC. | $11.08 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gina Lesnik listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.